July 21, 2017 Bio/Pharma/CRO Uncategorized

CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer

Basel, 21 July 2017 CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential treatment option for people with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) TECENTRIQ as a potential treatment option for people with... Read more

July 14, 2017 Bio/Pharma/CRO M&A, Partnerships

Canopy Biosciences Enters Bioprocessing Market with Launch of Host Cell Protein Detection Kits

Canopy Biosciences signs deal with Array Bridge to market kits for impurity analysis ST. LOUIS, July 13, 2017 /PRNewswire/ — Canopy BiosciencesTM, LLC, an emerging provider of gene editing and personalized medicine technologies, announced today that it will enter the bioprocessing field by marketing kits for host cell protein detection. Array Bridge, a biotech company that developed the... Read more

July 11, 2017 Bio/Pharma/CRO M&A, Partnerships

Sanofi to acquire Protein Sciences

– Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio – Jul 11, 2017 Paris, France – July 11, 2017 – Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States. Under the terms of the agreement, Sanofi will make an upfront payment of $650 million... Read more

July 10, 2017 Bio/Pharma/CRO Product Launch

Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine

Basel, 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate... Read more

July 10, 2017 Bio/Pharma/CRO Product Launch

Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine

Basel, 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate... Read more

July 7, 2017 Bio/Pharma/CRO

A message for our customers about the Pharmacovigilance Risk Assessment Committee recommendation on linear gadolinium agents

On July 7, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended to suspend broad spectrum intravenous use of linear gadolinium agents except for select indication of liver imaging. The PRAC’s recommendation applies to Europe only and is not https://www.genewsroom.com/press-releases/message-our-customers-about-pharmacovigilance-risk-assessment-committee Read more

June 29, 2017 Bio/Pharma/CRO Product Launch

Gyros Protein Technologies introduces new ADA solution for immunogenicity market

Developed to support assay development and validation for detection of anti-drug antibodies   Uppsala, Sweden, June 29th, 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity market.  ... Read more

June 28, 2017 Bio/Pharma/CRO

CordenPharma & GE Healthcare Offer Unique End-to-End Solution to Accelerate Oligonucleotide Drug Development

Chalfont St. Giles, UK and Plankstadt, Germany – June 28, 2017 – CordenPharma International and GE Healthcare’s Dharmacon business have entered a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery. The collaboration will address the speed and capacity challenges researchers face when transitioning from research and preclinical stages to drug development and... Read more